Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Inhibikase Therapeutics, Inc.

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsJun-30-23Mar-31-23Dec-31-22Sep-30-22Jun-30-22Mar-31-22Dec-31-21Sep-30-21
   10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Revenue:          
Total revenue  0.10.10.10.00.00.00.00.3
            Total revenue growth  1676.7%40.2%3169.9%-97.8%-99.5%-96.7%-98.9%771.7%
Revenue from Contract with Customer, Product and Service [Extensible List]          
Costs and expenses:          
Research and development  4.52.93.13.03.03.03.43.2
Selling, general and administrative  1.81.91.31.51.71.71.71.6
    Total costs and expenses  6.34.84.44.54.64.75.04.8
    Loss from operations  -6.2-4.7-4.3-4.5-4.6-4.6-5.0-4.5
            Operating margin  -5328.1%-7307.6%-6819.6%-61899.6%-70817.1%-10081.5%-259334.4%-1361.2%
Interest income (expense)  0.40.2   0.00.0 
    Net loss  -5.8-4.5-4.3-4.5-4.6-4.6-5.0-4.5
   
Other comprehensive income, net of tax          
Unrealized loss on marketable securities  -0.2       
    Comprehensive Loss  -5.9   -4.6   
   
Net loss per share - basic  ($1.11)($0.16)($0.17)($0.18)($1.10)($0.18)($0.20)($0.18)
Net loss per share - diluted  ($1.11)($0.16)($0.17)($0.18)($1.10)($0.18)($0.20)($0.18)
   
Weighted average number of common share - basic  5.227.525.225.24.225.218.225.1
Weighted average number of common share - diluted  5.227.525.225.24.225.218.225.1

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy